SAN JOSE, CALIFORNIA, UNITED STATES—August 26, 2024 /EINPresswire.com/ -- Biomed Industries, Inc. (Biomed), a leading biopharmaceutical company, revealed groundbreaking research on the close relationship between Alzheimer’s Disease and Diabetes-Obesity through its novel drug developments.
The paper, entitled “Associations Between Alzheimer’s Disease and Obesity: Clinical Trials of NA-831 for Alzheimer’s Disease and NA-931 for the Treatment of Obesity “was presented at the recent Alzheimer’s Association International Conference, July 26-August 1, 2024 in Philadelphia PA.
The link between dementia and weight loss is complex. Obesity has been linked to cognitive deficits, impaired long-term potentiation and synaptic plasticity, and a smaller brain volume, increasing the probability of developing Alzheimer’s disease (AD) and other dementias. Aging is linked to a change in body weight, adiposity, and variations in hormones and adipokines.
Obesity causes chronic inflammation in adipose tissue that leads to the dysregulation of homeostatic systems, which in turn leads to the development of various diseases, including those related to neurodegeneration.
Biomed’s drugs, NA-831 and NA-931, two related analogues have been shown to regulate homeostasis of the quadruple functions agonists: IGF-1, GLP-1 and GIP and Glucagon receptors. NA-831 exhibits neuroprotection, neurogenesis and memory enhancing properties for the treatment of Alzheimer's Disease (AD).
In a Phase 2 randomized double-blind placebo controlled clinical trial, NA-831, administered orally, showed a proof of safety and efficacy for the treatment of Alzheimer’s Disease. The drug was well-tolerated at 30 mg/day with no serious adverse events observed.
NA-931 works by regulating the Insulin and glucagon help maintain blood sugar levels. Glucagon helps prevent blood sugar from dropping, while insulin stops it from rising too high. Free Insulin like Growth Hormone (IGF-I) is elevated in obesity, playing a critical role in weight loss.
Glucagon-like peptide-1 (GLP-1) is a key regulator in maintaining glucose homeostasis by stimulating insulin secretion. GLP-1 and IGF-1 are interlinked having a primary role in metabolic functions, for treating Diabetes and Obesity. GIP is an incretin hormone produced in the gastrointestinal tract in response to nutrients.
NA 931 showed significant weight loss outcomes in animal studies and is now in a Phase 2A human clinical trial.
“It has been a remarkable discovery by our scientific team us to demonstrate the relationship between Alzheimer’s Disease , a neurodegenerative disease, and obesity, a metabolic disorder and the role our patented drugs play in both”, said Dr. Lloyd L. Tran, the Company’s CEO. He continued: “We are also finding significant relationships with other analogs of NA-831 and their promising results for the treatment of Major Depression Disorder(MDD), a liver disease known as MASH, stroke, and the rare disease Rett Syndrome. It is a very exciting time for us in terms of our drug development platform.”
About Biomed Industries, Inc.:
Biomed Industries, Inc. is a pioneering bio-pharmaceutical company dedicated to developing and commercializing novel drug therapeutics to address unmet medical needs. The company's research team has developed a new platform of drugs targeting Alzheimer’s disease, ALS, Traumatic Brain Injury, Major Depressive Disorder (MDD), Diabetes Obesity, MASH, Stroke, and rare diseases, including Rett Syndrome.
For further information, please visit Biomed Industries' official website:
https://www.biomedind.com
CONTACT
Michael Willis
Biomed Industries, Inc.
San Jose, CA 95131 USA
Tel. 800-824-5135
Email: media@biomedind.com
https://www.biomedind.com
For more news, please visit our News page.
For further information about Biomed Industries, Inc., please contact us.